CClinicalTrials.gg
Enrolling by invitationNCT07060300CAREPICCUpdated Jul 24, 2025

Comprehensive Assessment of Reactions to Pharmacogenetics in Complex Care Patients

An interventional study of Agree to Pharmacogenetic Testing in Pediatric Medical Complexity Based on PMCA Score of 3, sponsored by Children's Hospital Medical Center, Cincinnati. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Sex
All
01

Study summary

The goal of this clinical trial is to determine the feasibility and acceptability of Pharmacogenetic Testing, and the attitudes towards the same in caregivers of complex care patients in Cincinnati, OH. The main question[s] it aims to answer are:

  1. With financial and access barriers removed, do caregivers of complex care patients agree to receive Pharmacogenetic testing for their children?
  2. With financial and access barriers removed, what are some remaining barriers to implementation of pharmacogenetics testing?
  3. What are the prevailing attitudes towards Pharmacogenetic testing in the complex care population?

Participants will be offered pharmacogenetic testing for their child free of charge, and will be asked to fill out a voluntary survey. Certain caregivers of complex care patients may be asked if they want to participate in a short semi-structured interview.

Read the detailed description

Through this research, the investigators expect to have successfully provided pharmacogenetic testing to a large cohort of patients in Cincinnati Children's Complex Care Clinic, allowing for an improved understanding of how to provide pharmacogenetic testing in children with medical complexity (feasibility) and of caregiver attitudes about pharmacogenetic testing for their children (acceptability). The knowledge gained from this study will be used to inform future program implementations in children with medical complexity (CMC) populations. Successfully tested patients will also provide for future studies to measure the effectiveness of pharmacogenetic testing in this population, as well as prescriber behavior when provided pharmacogenetic testing results.

02

Conditions studied

  • Pediatric Medical Complexity Based on PMCA Score of 3

Keywords

  • Medical Compexity
  • Pharmacogenetics
03

In context

Lead sponsor

Children's Hospital Medical Center, Cincinnati is the lead sponsor of 661 studies on the registry; 134 are open to participants now.

Of its 54 completed or terminated interventional studies of FDA-regulated products, 30 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients who score a 3 on the Pediatric Medical Complexity Algorithm
  2. Patients whose primary care providers are those at the Cincinnati Children's Complex Care Clinic

    1. Patients attending the Cincinnati Children's Hospital Complex Care Clinic for well child visit
    2. Patients attending the Cincinnati Children's Hospital Complex Care Clinic for chronic care management visits
    3. Legal Guardian is present at time of clinical visit

Exclusion criteria

Exclusion Criteria:

  • Patients attending the Complex Care Clinic for acute illness.
  • Patients who have previously received Pharmacogenetic Testing.
  • Patients deemed ineligible for approach by the clinical team.
  • Patients who are wards of the state.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Accept Pharmacogenetic Testing

    Caregivers who agree to receive Pharmacogenetic testing for their child

    Other: Agree to Pharmacogenetic Testing

Interventions

  • OtherAgree to Pharmacogenetic Testing

    Caregivers agree to receive pharmacogenetic testing for their child.

06

What researchers measure

Primary outcomes

  1. Percentage of Caregivers of Medically Complex Patients who accept the offer of Free Clinical Pharmacogenetic Testing

    What portion of caregivers accept pharmacogenetic testing for their children when the barriers of access and financial burden are removed

    Time frame: Day 1

Secondary outcomes

  1. Barriers to acceptance of Pharmacogenetic testing

    Barriers will be elicited through semi-structured interviews on consenting caregivers. We will utilize thematic analysis to identify and assess potential remaining barriers other than cost and access that inhibit the feasibility of pharmacogenetic testing in patients with medical complexity

    Time frame: 6 months

  2. Facilitators to acceptance of pharmacogenetic testing

    Facilitators will be elicited through semi-structured interviews on consenting caregivers. We will utilize thematic analysis to identify and assess facilitators that enhance the feasibility of pharmacogenetic testing in patients with medical complexity

    Time frame: 6 months

07

Study locations

1 site
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
08

References and documents

Individual participant data

Plan to share: No — No specific Identifiable Patient Health Information (PHI) will be shared. However, aggregated data and de-identified info may be shared with IRB pre-approved collaborators.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07060300
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Responsible party
Sonya Tang Girdwood (Associate Professor of Pediatrics, Children's Hospital Medical Center, Cincinnati) — Principal investigator
First posted
Jul 11, 2025
Start date
Jul 15, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 24, 2025

Study contacts

Sonya Tang Girdwood
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion